Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - PHARMABIZ.COM - A la Une - 15/Jul 00:00
Immutep announces positive results from TACTI─003 phase IIb trial of efti in combo with Keytruda to treat HNSCC patients with negative PD─L1 expression
Immutep Limited (Immutep), a clinical─stage biotechnology company developing novel LAG─3 immunotherapies for cancer and autoimmune disease, announces positive results from Cohort B of the TACTI─003
Articles similaires
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome
pharmabiz.com - 04/Sep 00:00
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome
pharmabiz.com - 04/Sep 00:00
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Breakthrough T1D and Integrated Nanotherapeutics Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes
financialpost.com - 09/Sep 16:02
VANCOUVER, British Columbia & NEW YORK — Integrated Nanotherapeutics (INT), a biotechnology company developing innovative treatments for...
Breakthrough T1D and Integrated Nanotherapeutics Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes
financialpost.com - 09/Sep 16:02
VANCOUVER, British Columbia & NEW YORK — Integrated Nanotherapeutics (INT), a biotechnology company developing innovative treatments for...
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
zacks.com - 30/Aug 16:07
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of...
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
drugs.com - 03/Sep 01:09
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma
zacks.com - 04/Sep 14:51
MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.
Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma
zacks.com - 04/Sep 14:51
MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.
Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases
pharmabiz.com - 05/Sep 00:00
Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...
Les derniers communiqués
-
Aucun élément